{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:08:44Z","timestamp":1777936124111,"version":"3.51.4"},"reference-count":23,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"crossref","award":["Division of Internal Medicine Developmental Funds"],"award-info":[{"award-number":["Division of Internal Medicine Developmental Funds"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"crossref","award":["Moon Shots Program"],"award-info":[{"award-number":["Moon Shots Program"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R03CA219760"],"award-info":[{"award-number":["R03CA219760"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0597-x","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T13:03:59Z","timestamp":1557839039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare"],"prefix":"10.1136","volume":"7","author":[{"given":"Sang T.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Bittar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amado J.","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roza","family":"Nurieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"issue":"6230","key":"597_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361.","journal-title":"Science"},{"issue":"11","key":"597_CR2","first-page":"5935","volume":"37","author":"JT Pento","year":"2017","unstructured":"Pento JT. Monoclonal antibodies for the treatment of Cancer. Anticancer Res. 2017;37(11):5935\u20139.","journal-title":"Anticancer Res"},{"issue":"1","key":"597_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"597_CR4","doi-asserted-by":"publisher","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"C Calabrese","year":"2017","unstructured":"Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412.","journal-title":"RMD Open"},{"issue":"3","key":"597_CR5","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"597_CR6","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","volume":"76","author":"R Belkhir","year":"2017","unstructured":"Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76(10):1747\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"597_CR7","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","volume":"76","author":"ST Kim","year":"2017","unstructured":"Kim ST, Tayar J, Trinh VA, Suarez-Almazor M, Garcia S, Hwu P, Johnson DH, Uemura M, Diab A. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"597_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.0105-2896.2009.00860.x","volume":"233","author":"F Martinon","year":"2010","unstructured":"Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev. 2010;233(1):218\u201332.","journal-title":"Immunol Rev"},{"issue":"1","key":"597_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1165\/rcmb.2015-0146OC","volume":"54","author":"YR Yu","year":"2016","unstructured":"Yu YR, Hotten DF, Malakhau Y, Volker E, Ghio AJ, Noble PW, Kraft M, Hollingsworth JW, Gunn MD, Tighe RM. Flow cytometric analysis of myeloid cells in human blood, bronchoalveolar lavage, and lung tissues. Am J Respir Cell Mol Biol. 2016;54(1):13\u201324.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"597_CR10","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10753-012-9496-8","volume":"35","author":"N Yu","year":"2012","unstructured":"Yu N, Li X, Song W, Li D, Yu D, Zeng X, Li M, Leng X, Li X. CD4(+)CD25 (+)CD127 (low\/\u2212) T cells: a more specific Treg population in human peripheral blood. Inflammation. 2012;35(6):1773\u201380.","journal-title":"Inflammation"},{"issue":"6","key":"597_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrrheum.2012.58","volume":"8","author":"JE Craft","year":"2012","unstructured":"Craft JE. Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol. 2012;8(6):337\u201347.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"597_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448\u201357.","journal-title":"Nat Immunol"},{"issue":"5","key":"597_CR13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1586\/1744666X.2014.894886","volume":"10","author":"RC Russo","year":"2014","unstructured":"Russo RC, Garcia CC, Teixeira MM, Amaral FA. The CXCL8\/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593\u2013619.","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"597_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","volume":"14","author":"LH Calabrese","year":"2018","unstructured":"Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14(10):569\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"597_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","volume":"140","author":"DL Kastner","year":"2010","unstructured":"Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140(6):784\u201390.","journal-title":"Cell"},{"issue":"7081","key":"597_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341.","journal-title":"Nature"},{"issue":"7198","key":"597_CR17","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature06939","volume":"453","author":"SC Eisenbarth","year":"2008","unstructured":"Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122\u20136.","journal-title":"Nature"},{"issue":"8","key":"597_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/ni.1631","volume":"9","author":"V Hornung","year":"2008","unstructured":"Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847\u201356.","journal-title":"Nat Immunol"},{"issue":"26","key":"597_CR19","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1056\/NEJMra1511117","volume":"374","author":"AK Rosenthal","year":"2016","unstructured":"Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374(26):2575\u201384.","journal-title":"N Engl J Med"},{"issue":"12","key":"597_CR20","doi-asserted-by":"publisher","first-page":"6488","DOI":"10.4049\/jimmunol.1203215","volume":"190","author":"L Pang","year":"2013","unstructured":"Pang L, Hayes CP, Buac K, Yoo DG, Rada B. Pseudogout-associated inflammatory calcium pyrophosphate dihydrate microcrystals induce formation of neutrophil extracellular traps. J Immunol. 2013;190(12):6488\u2013500.","journal-title":"J Immunol"},{"issue":"9","key":"597_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1038\/nm.2847","volume":"18","author":"BG Yipp","year":"2012","unstructured":"Yipp BG, Petri B, Salina D, Jenne CN, Scott BN, Zbytnuik LD, Pittman K, Asaduzzaman M, Wu K, Meijndert HC, et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat Med. 2012;18(9):1386\u201393.","journal-title":"Nat Med"},{"issue":"26","key":"597_CR22","doi-asserted-by":"publisher","first-page":"eaao4747","DOI":"10.1126\/sciimmunol.aao4747","volume":"3","author":"N Krishnamoorthy","year":"2018","unstructured":"Krishnamoorthy N, Douda DN, Bruggemann TR, Ricklefs I, Duvall MG, Abdulnour RE, Martinod K, Tavares L, Wang X, Cernadas M, et al. Neutrophil cytoplasts induce TH17 differentiation and skew inflammation toward neutrophilia in severe asthma. Sci Immunol. 2018;3(26):eaao4747.","journal-title":"Sci Immunol"},{"issue":"3","key":"597_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/0049-0172(92)90019-A","volume":"22","author":"AC Jones","year":"1992","unstructured":"Jones AC, Chuck AJ, Arie EA, Green DJ, Doherty M. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum. 1992;22(3):188\u2013202.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0597-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0597-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0597-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:44:18Z","timestamp":1601055858000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0597-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["597"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0597-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"11 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Synovial fluid collection for the study was approved by an Institutional Review Board at the University of Texas MD Anderson Cancer Center (IRB #: PA16-0935). The patient signed consent allowing use of his biospecimens.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Neelapu has received research support from Kite\/Gilead, Celgene, Cellectis, Poseida, Merck, Acerta, Karus, and BMS; served as consultant and advisory board member for Kite\/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, and Merck. Dr. Suarez-Almazor has received consultant fees from Pfizer, Eli Lilly, AbbVie and Bristol Myers Squibb unrelated to this work. Dr. Nurieva is a consultant for Nurix, Inc. studies that are not related to this work. Other authors declared no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"126"}}